Clinical Trials Logo

Filter by:
NCT ID: NCT00148356 Completed - Clinical trials for Coronary Artery Disease

Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries

ZoMaxx™ I
Start date: September 2004
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries. The study is designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that has proven superior to bare metal stents and is a recognized standard of care.

NCT ID: NCT00147732 Completed - Larynx Carcinoma Clinical Trials

Randomized Trial of ARCON in Larynx Cancer

Start date: April 2001
Phase: Phase 3
Study type: Interventional

TITLE: A multicentre, randomised, phase III clinical trial comparing accelerated radiotherapy with accelerated radiotherapy plus carbogen and nicotinamide (ARCON) in clinical stage T2-4 laryngeal carcinoma. PRIMARY OBJECTIVE: Does the addition of carbogen and nicotinamide to a schedule of accelerated radiotherapy in patients with clinical stage T2-4 laryngeal carcinoma improve local primary tumour control? Definitive analysis will be performed on local control rates at two years after completion of radiotherapy. SECONDARY OBJECTIVES: Does the addition of carbogen and nicotinamide - increase the larynx preservation rate? - increase the regional control rate? - increase the toxicity of accelerated radiotherapy? - improve the overall quality of life? - improve the disease-free survival? - improve the overall survival? STUDY DESIGN: An open-label, randomised clinical trial assigning patients in a 1:1 ratio to one of the following treatment arms: - accelerated radiotherapy - accelerated radiotherapy plus carbogen and nicotinamide PATIENT CHARACTERISTICS AND NUMBER: 344 patients with clinical T2-4 laryngeal carcinoma MEASUREMENTS: - time to local failure - time to regional failure - survival with functional larynx - overall and disease-free survival - frequency and severity of complications related to radiotherapy and carbogen and nicotinamide - quality of life assessment

NCT ID: NCT00147693 Completed - Alzheimer Disease Clinical Trials

Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach?

Start date: June 2005
Phase: N/A
Study type: Interventional

The objective is to ascertain the potential efficiency of a systematic care programme for caregivers of dementia patients. The research questions are: - What are the costs and benefits of the Systematic Care Programme - Dementia (SCP-Dementia), as compared with usual care? - What are the effects on the quality of life of patients and informal caregivers (spouse, relative), as compared with usual care?

NCT ID: NCT00147602 Completed - Clinical trials for Cardiovascular Disease

Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

SPARCL
Start date: November 1998
Phase: Phase 4
Study type: Interventional

To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.

NCT ID: NCT00147004 Completed - Shock, Septic Clinical Trials

Corticosteroid Therapy of Septic Shock - Corticus

Corticus
Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether steroids decrease 28-day mortality in patients with septic shock.

NCT ID: NCT00146770 Completed - Clinical trials for Mucopolysaccharidosis I

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Start date: May 2001
Phase: Phase 3
Study type: Interventional

This study is being conducted to collect additional long-term efficacy and safety data of Aldurazyme® (laronidase) patients with MPS I disease. Patients who were previously enrolled in the Phase 3 Double-Blind Study will be enrolled in this study.

NCT ID: NCT00146757 Completed - Clinical trials for Mucopolysaccharidosis I

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

Start date: October 2002
Phase: Phase 2
Study type: Interventional

The main objectives of this study are to evaluate the safety and pharmacokinetics (PK) of enzyme replacement therapy with recombinant human alpha-L-iduronidase [Aldurazyme® (laronidase)] in mucopolysaccharidosis I (MPS I) patients less than 5 years old. Efficacy measurements will also be evaluated in this study.

NCT ID: NCT00146705 Completed - Chronic Hepatitis B Clinical Trials

Long Term Follow-up of Pegylated-Interferon Alpha-2b

Start date: May 2005
Phase: N/A
Study type: Observational

The aim of this study was to investigate the long term outcome of Peginterferon alpha-2b with or without the addition of lamivudine in patients with chronic hepatitis B

NCT ID: NCT00146328 Completed - HIV Infections Clinical Trials

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

Start date: April 2001
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications.

NCT ID: NCT00146016 Completed - Chronic Hepatitis C Clinical Trials

Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients

Start date: February 2000
Phase: Phase 3
Study type: Interventional

* Adding Amantadine to standard anti-viral treatment can improve sustained response rates in patients with chronic hepatitis C